User profiles for "author:Brian Gastman"
Brian GastmanProfessor Surgery, Cleveland Clinic Lerner College of Medicine Verified email at ccf.org Cited by 7902 |
What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature
Y Gulleth, N Goldberg, RP Silverman… - Plastic and …, 2010 - journals.lww.com
Background: Current management of basal cell carcinoma is surgical excision. Most
resections use predetermined surgical margins. The basis of ideal resection margins is …
resections use predetermined surgical margins. The basis of ideal resection margins is …
Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy
BV Manyam, B Gastman, AY Zhang, CA Reddy… - Journal of the American …, 2015 - Elsevier
Background Immunosuppressed patients have higher rates of cutaneous squamous cell
carcinoma of the head and neck. Objective This study reviews the effect of immune status on …
carcinoma of the head and neck. Objective This study reviews the effect of immune status on …
NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines
SM Swetter, JA Thompson, MR Albertini… - Journal of the National …, 2021 - jnccn.org
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …
Malignant melanoma: diagnostic and management update
T Knackstedt, RW Knackstedt, R Couto… - Plastic and …, 2018 - journals.lww.com
Strides in melanoma surveillance, detection, and treatment continue to be made. The
American Joint Committee on Cancer Eighth Edition Cancer Staging System has improved …
American Joint Committee on Cancer Eighth Edition Cancer Staging System has improved …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …
melanoma have been significantly revised over the past few years in response to emerging …
Human γδ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement
A Maniar, X Zhang, W Lin, BR Gastman… - Blood, The Journal …, 2010 - ashpublications.org
Natural killer (NK) cells are innate effector lymphocytes that control the growth of major
histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes …
histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes …
Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology
CK Bichakjian, T Olencki, SZ Aasi, M Alam… - Journal of the National …, 2018 - jnccn.org
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on
areas impacted by recently emerging data, including sections describing MCC risk factors …
areas impacted by recently emerging data, including sections describing MCC risk factors …
Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
BR Gastman, Y Atarashi, TE Reichert, T Saito, L Balkir… - Cancer research, 1999 - AACR
Recent reports have variously described expression of Fas ligand (FasL) or its absence in
human tumors. The importance of the Fas-FasL mechanism for the immune evasion by …
human tumors. The importance of the Fas-FasL mechanism for the immune evasion by …
A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4–ERK5 axis
Although IL-17 is emerging as an important cytokine in cancer promotion and progression,
the underlining molecular mechanism remains unclear. Previous studies suggest that IL-17 …
the underlining molecular mechanism remains unclear. Previous studies suggest that IL-17 …
[HTML][HTML] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
JM Kirkwood, M Del Vecchio, J Weber, C Hoeller… - Nature Medicine, 2023 - nature.com
Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …